Currently, bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF), is FDA approved for the treatment of metastatic colorectal cancer (mCRC), metastatic renal cell cancer (mRCC), non-small cell lung cancer (NSCLC) and glioblastoma, while its treatment efficacy in other malignancies is still being investigated. Here, VEGFA is linked to metastatic colorectal cancer.